Peroxisome proliferators and fatty acids negatively regulate liver X receptor-mediated activity and sterol biosynthesis

Journal of Steroid Biochemistry and Molecular Biology

Volumn 77, Issue 1, 2001, Pages 59-71

  Johnson, Timothy E ^a   Ledwith, Brian J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Fatty acids; Liver X receptors; Mevalonate pathway; Peroxisome proliferator activated receptors; Peroxisome proliferators

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; ARACHIDONIC ACID DERIVATIVE; CELL NUCLEUS RECEPTOR; CIPROFIBRIC ACID; FIBRIC ACID DERIVATIVE; ICOSATETRAYNOIC ACID; LONG CHAIN FATTY ACID; MEVALONIC ACID; MEVINOLIN; MONO ETHYLHEXYLPHTHALATE; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHTHALIC ACID DERIVATIVE; PIRINIXIC ACID; POLYUNSATURATED FATTY ACID; STEROL; TUMOR PROMOTER; UNCLASSIFIED DRUG; ZARAGOZIC ACID A;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INDUCTION; HEPATOMA CELL; IC 50; NONHUMAN; RAT; REPORTER GENE; RODENT; STEROL SYNTHESIS;

ACYL-COA OXIDASE; ANIMALS; COS CELLS; DNA-BINDING PROTEINS; FATTY ACIDS; OXIDOREDUCTASES; PEROXISOME PROLIFERATORS; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RECEPTORS, THYROID HORMONE; STEROLS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

RODENTIA;

EID: 0035007931     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(01)00027-9     Document Type: Article

References (63)

1. James N.H., Gill J.H., Brindle R., Woodyatt N.J., Macdonald N., Rolfe M., Hasmall S.C., Tugwood J.D., Holden P.R., Roberts R.A. Peroxisome proliferator-activated receptor (PPAR) α-regulated growth responses and their importance to hepatocarcinogenesis. Toxicol. Lett. 102-103:1998;91-96.
2. Desvergne B., IJpenberg A., Devchand P.R., Wahli W. The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling. J. Steroid. Biochem. Mol. Biol. 65:1998;65-74.
3. Nunez S.B., Medin J.A., Keller H., Wang K., Ozato K., Wahli W., Segars J. Retinoid X receptor β and peroxisome proliferator-activated receptor activate an estrogen response element. Recent. Prog. Horm. Res. 50:1995;409-416.
4. Peters J.M., Aoyama T., Cattley R.C., Nobumitsu U., Hashimoto T., Gonzalez F.J. Role of peroxisome proliferator-activated receptor α in altered cell cycle regulation in mouse liver. Carcinogenesis. 19:1998;1989-1994.
5. Ledwith B.J., Johnson T.E., Wagner L.K., Pauley C.J., Manam S., Galloway S.M., Nichols W.W. Growth regulation by peroxisome proliferators: opposing activities in early and late G1. Cancer Res. 56:1996;3257-3264.
6. Ledwith B.J., Manam S., Troilo P., Joslyn D.J., Galloway S.M., Nichols W.W. Activation of immediate-early gene expression by peroxisome proliferators in vitro. Mol. Carcinog. 8:1993;20-27.
7. Ledwith B.J., Pauley C.J., Wagner L.K., Rokos C.L., Alberts D.W., Manam S. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells. J. Biol. Chem. 272:1997;3707-3714.
8. Rokos C.L., Ledwith B.J. Peroxisome proliferators activate extracellular signal-regulated kinases in immortalized mouse liver cells. J. Biol. Chem. 272:1997;13452-13457.
9. Belury M.A., Moya C.S., Sun H., Snyder E., Davis J.W., Cunningham M.L., Vanden H.J. Comparison of dose-response relationships for induction of lipid metabolizing and growth regulatory genes by peroxisome proliferators in rat liver. Toxicol. Appl. Pharmacol. 151:1998;254-261.
10. Cosulich S., James N., Roberts R.A. Role of MAP kinase signaling pathways in the mode of action of peroxisome proliferators. Carcinogenesis. 21:2000;579-583.
11. Rao K.N. The significance of the cholesterol biosynthetic pathway in cell growth and carcinogenesis. Anticancer. Res. 15:1995;309-314.
12. Willy P.J., Umesono K., Ong E.S., Evans R.M., Heyman R.A., Mangelsdorf D.J. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes. Dev. 9:1995;1033-1045.
13. Shinar D.M., Endo N., Rutledge S.J., Vogel R., Rodan G.A., Schmidt A. NER, a new member of the gene family encoding the human steroid hormone nuclear receptor. Gene. 147:1994;273-276.
14. Song C., Kokontis J.M., Hiipakka R.A., Liao S. Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc. Natl. Acad. Sci. USA. 91:1994;10809-10813.
15. Apfel R., Benbrook D., Lernhardt E., Ortiz M.A., Salbert G., Pfahl M. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol. Cell Bio. 14:1994;7025-7035.
16. Forman B.M., Ruan B., Chen J., Schroepfer-GJ J., Evans R.M. The orphan nuclear receptor LXRα is positively and negatively regulated by distinct products of mevalonate metabolism. Proc. Natl. Acad. Sci. USA. 94:1997;10588-10593.
17. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXRα Nature. 383:1996;728-731.
18. Lehmann J.M., Kliewer S.A., Moore L.B., Smith O.T., Oliver B.B., Su J.L., Sundseth S.S., Winegar D.A., Blanchard D.E., Spencer T.A., Willson T.M. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272:1997;3137-3140.
19. Janowski B.A., Grogan M.J., Jones S.A., Wisely G.B., Kliewer S.A., Corey E.J., Mangelsdorf D.J. Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ Proc. Natl. Acad. Sci. USA. 96:1999;266-271.
20. Peet D.J., Turley S.D., Ma W., Janowski B.A., Lobaccaro J.M., Hammer R.E., Mangelsdorf D.J. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα Cell. 93:1998;693-704.
21. Repa J.J., Mangelsdorf D.J. Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr. Opin. Biotech. 10:2000;557-563.
22. Krisans S.K. Cell compartmentalization of cholesterol biosynthesis. Ann. NY Acad. Sci. 804:1996;142-164.
23. Miyata K.S., McCaw S.E., Patel H.V., Rachubinski R.A., Capone J.P. The orphan nuclear hormone receptor LXRα interacts with the peroxisome proliferator-activated receptor and inhibits peroxisome proliferator signaling. J. Biol. Chem. 271:1996;9189-9192.
24. Petit D., Bonnefis M.T., Rey C., Infante R. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats. Atherosclerosis. 74:1988;215-225.
25. Rebuffat P., Belloni A.S., Cavallini L., Mazzocchi G., Meneghelli V., Nussdorfer G.G. Effect of mevinolin on rat hepatocytes: a morphometric study. Exp. Pathol. 35:1988;133-139.
26. Schmidt A., Endo N., Rutledge S.J., Vogel R., Shinar D., Rodan G.A. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol. 6:1992;1634-1641.
27. Bocan T.M., Ferguson E., McNally W., Uhlendorf P.D., Bak M.S., Dehart P., Sliskovic D.R., Roth B.D., Krause B.R., Newton R.S. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim. Biophys. Acta. 1123:1992;133-144.
28. Poosch M.S., Yamazaki R.K. Determination of peroxisomal fatty acyl-CoA oxidase activity using a lauroyl-CoA-based fluorometric assay. Biochim. Biophys. Acta. 884:1986;585-593.
29. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895.
30. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 347:1990;645-650.
31. Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ Proc. Natl. Acad. Sci. USA. 94:1997;4312-4317.
32. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., Devchand P., Wahli W., Willson T.M., Lenhard J.M., Lehmann J.M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ Proc. Natl. Acad. Sci. USA. 94:1997;4318-4323.
33. Clarke S.D., Jump D.B. Dietary polyunsaturated fatty acid regulation of gene transcription. Annu. Rev. Nutr. 14:1994;83-98.
34. Jump D.B., Ren B., Clarke S., Thelen A. Effects of fatty acids on hepatic gene expression. Prostaglandins Leukot Essent Fatty Acids. 52:1995;107-111.
35. Ortiz M.B., Goin M., Gomez-de A.M., Hammarstrom S., Jimenez-de A.L. Mevalonate dependency of the early cell cycle mitogenic response to epidermal growth factor and prostaglandin F2α in Swiss mouse 3T3 cells. J. Cell Physiol. 162:1995;139-146.
36. Haughom B., Spydevold O. The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. Biochim. Biophys. Acta. 1128:1992;65-72.
37. Osumi T., Yokota S., Hashimoto T. Proliferation of peroxisomes and induction of peroxisomal β-oxidation enzymes in rat hepatoma H4IIEC3 by ciprofibrate. J. Biochem. Tokyo. 108:1990;614-621.
38. Chevalier S., Roberts R.A. G1-arrested FaO cells re-enter the cell cycle upon stimulation with the rodent non-genotoxic hepatocarcinogen nafenopin. Carcinogenesis. 20:1999;1209-1213.
39. Wiebel F.J., Park S.S., Kiefer F., Gelboin H.V. Expression of cytochromes P-450 in rat hepatoma cells. Analysis by monoclonal antibodies specific for cytochromes P-450 from rat liver induced by 3-methylcholanthrene or phenobarbital. Eur. J. Biochem. 145:1984;455-462.
40. Bayly A.C., French N.J., Dive C., Roberts R.A. Non-genotoxic hepatocarcinogenesis in vitro: the FaO hepatoma line responds to peroxisome proliferators and retains the ability to undergo apoptosis. J. Cell Sci. 104:1993;307-315.
41. Roscher E., Wiebel F.J. Mutagenicity, clastogenicity and cytotoxicity of procarcinogens in a rat hepatoma cell line competent for xenobiotic metabolism. Mutagenesis. 3:1988;269-276.
42. Berger J., Leibowitz M.D., Doebber T.W., Elbrecht A., Zhang B., Zhou G., Biswas C., Cullinan C.A., Hayes N.S., Li Y., Tanen M., Ventre J., Wu M.S., Berger G.D., Mosley R., Marquis R., Santini C., Sahoo S.P., Tolman R.L., Smith R.G., Moller D.E. Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects. J. Biol. Chem. 274:1999;6718-6725.
43. Schoonjans K., Martin G., Staels B., Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 8:1997;159-166.
44. Baxter A., Fitzgerald B.J., Hutson J.L., McCarthy A.D., Motteram J.M., Ross B.C., Sapra M., Snowden M.A., Watson N.S., Williams R.J. Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J. Biol. Chem. 267:1992;11705-11708.
45. Bergstrom J.D., Dufresne C., Bills G.F., Nallin O.M., Byrne K. Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase. Annu. Rev. Microbiol. 49:1995;607-639.
46. Peters J.M., Zhou Y.C., Ram P.A., Lee S.S., Gonzalez F.J., Waxman D.J. Peroxisome proliferator-activated receptor α required for gene induction by dehydroepiandrosterone-3 β-sulfate. Mol. Pharmacol. 50:1996;67-74.
47. Li J.R., Holets R.J., Kottke B.A. Effect of probucol on cholesterol metabolism in the rat. Atherosclerosis. 36:1980;559-565.
48. Hashimoto F., Hamada S., Hayashi H. Effect of gemfibrozil on centrifugal behavior of rat peroxisomes and activities of peroxisomal enzymes involved in lipid metabolism. Biol. Pharm. Bull. 20:1997;315-321.
49. Hashimoto F., Ishikawa T., Hamada S., Hayashi H. Effect of gemfibrozil on lipid biosynthesis from acetyl-CoA derived from peroxisomal β-oxidation. Biochem. Pharmacol. 49:1995;1213-1221.
50. Rose K.G., Bar T.J. Inhibition of lipid synthesis by β,β′-tetramethyl-substituted, C14-C22, α,ω-dicarboxylic acids in cultured rat hepatocytes. J. Biol. Chem. 260:1985;8411-8415.
51. Frenkel B., Mayorek N., Hertz R., Bar T.J. The hypochylomicronemic effect of β,β′-methyl-substituted hexadecanedioic acid (MEDICA 16) is mediated by a decrease in apolipoprotein C-III. J. Biol. Chem. 263:1988;8491-8497.
52. Hashimoto F., Taira S., Hayashi H. Comparison of the effects of gemfibrozil and clofibric acid on peroxisomal enzymes and cholesterol synthesis of rat hepatocytes. Biol. Pharm. Bull. 21:1998;1142-1147.
53. Cheema S.K., Agellon L.B. The murine and human cholesterol 7-α-hydroxylase gene promoters are differentially responsive to regulation by fatty acids mediated via peroxisome proliferator-activated receptor α J. Biol. Chem. 275:2000;12530-12536.
54. Marrapodi M., Chiang J.Y.L. Peroxisome proliferator-activated receptor α (PPAR-α) and agonist inhibit cholesterol 7-α hydroxylase gene (CYP7A1) transcription. J. Lipid Res. 41:2000;514-520.
55. Tobin K.A.R., Steineger H.H., Alberti S., Spydevold O., Auwerx J., Gustafsson J.A., Nebb H.I. Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-α Mol. Endocrinol. 14:2000;741-752.
56. Marsman D.S., Cattley R.C., Conway J.G., Popp J.A. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats. Cancer. Res. 48:1988;6739-6744.
57. Wada N., Marsman D.S., Popp J.A. Dose-related effects of the hepatocarcinogen, Wy-14,643, on peroxisomes and cell replication. Fundam. Appl. Toxicol. 18:1992;149-154.
58. Grasl K.B., Huber W., Just W., Gibson G., Schulte H.R. Enhancement of peroxisomal enzymes, cytochrome P-452 and DNA synthesis in putative preneoplastic foci of rat liver treated with the peroxisome proliferator nafenopin. Carcinogenesis. 14:1993;1007-1012.
59. Cunningham M.L., Soliman M.S., Badr M.Z., Matthews H.B. Rotenone, an anticarcinogen, inhibits cellular proliferation but not peroxisome proliferation in mouse liver. Cancer. Lett. 95:1995;93-97.
60. Lake B.G., Evans J.G., Cunninghame M.E., Price R.J. Comparison of the hepatic effects of nafenopin and WY-14,643 on peroxisome proliferation and cell replication in the rat and Syrian hamster. Environ. Health Perspect. 101:1993;241-247.
61. Eason C.T., Powles P., Henry G., Spencer A.J., Pattison A., Bonner F.W. The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat. Xenobiotica. 19:1989;913-925.
62. Cayen M.N. Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man. Pharmacol. Ther. 29:1985;157-204.
63. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65:1996;241-269.